Home > Insider Trading > Filing (0001415889-24-019438)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1192448	Glaukos Corp	GKOS	Surgical & Medical Instruments & Apparatus (3841)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1705850	E Joseph Gilliam	C/O Glaukos Corporation One Glaukos Way Aliso Viejo CA 92656	President & Coo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-07-05	2,250	$69.30	104,095	No	4	M	Direct
Common Stock	Disposition	2024-07-05	2,250	$121.39	101,845	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-07-05	2,250	$69.30	2,250	$69.30

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,981		2029-03-14	No	4	M	Direct

Footnotes

Includes 76,419 restricted stock units that have not yet vested or been delivered to the Reporting Person.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024.
This transaction was executed in multiple trades at prices ranging from $121.28 to $121.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024.
This option was granted on March 14, 2019 and had a four-year vesting schedule in which 25% vested on the first anniversary of the grant date and the remainder vested in equal monthly installments for 36 months thereafter, such that the stock option vested in full on the four-year anniversary of the grant date.